The submission was through the centralized procedure and this new formulation allows once-daily dosing: Competact (pioglitazone HCl and metfomin HCl) is currently available in some European countries as a product to be taken twice-daily.
Takeda is said to be the originator of thiazolidinedione derivatives with the development of Actos (pioglitazone), which directly targets insulin resistance. Metformin acts primarily by reducing the amount of glucose produced by the liver. These medications work in combination to help patients with type 2 diabetes manage their blood glucose levels, the company said.
Masaomi Miyamoto, general manager of the pharmaceutical development division of Takeda, said: “This product will provide an additional treatment option for healthcare professionals and patients with type 2 diabetes. Takeda believes this product will further enhance our diabetes franchise in European markets.”